FMT in Obesity: RYGB vs. LEAN vs. Autologous FMT

Exclusion Criteria

• •Non-Compliance
• •Insulin dependent diabetes mellitus, treated with GLP-1 agonists or poorly controlled on oral antidiabetic medications (HbA1C \> 8%)
• •Use of any weight loss medication or participation in a weight loss program
• •History of recent body weight change (defined as body weight loss or body weight gain of ≥ 5 kg within the two months preceding study enrolment).
• •Use of immunosuppressive medication or immune modulators (glucocorticoids, methotrexate, tacrolimus, cyclosporine, thalidomide, interleukin-10 or -11) within the last three months preceding study enrolment.
• •Congenital or acquired immunodeficiencies.
• •Anatomical reconstruction of the nutrient passage (i.e. hemicolectomy, resection of small bowel, gastrectomy, sleeve gastrectomy, gastric bypass surgery, biliopancreatic diversion, fundoplication etc) or cholecystectomy.
• •Chronic diarrhoea
• •History of serious chronic disease including malignancy, rheumatic heart disease, endocarditis, or valvular disease (due to risk of bacteremia)
• •Any condition, based on clinical judgment that may make study participation unsafe
• •Pregnancy or Breast Feeding
• •Intake of pre-, pro- or antibiotics within \< 3 months before study entry
• •Use of immunosuppressive medication or immune modulators (glucocorticoids, methotrexate, tacrolimus, cyclosporine, thalidomide, interleukin-10 or -11) within the last three months preceding study enrolment.
• •Congenital or acquired immunodeficiencies.
• •Chronic or acute infectious diseases (specified under 6.2.1)
• •Drug abuse
• •Anatomical reconstruction of the nutrient passage other than surgical RYGB configuration (i.e. hemicolectomy, resection of small bowel, fundoplication, LSG-to-RYGB transformation etc) or cholecystectomy.
• •History of recent body weight change (defined as body weight loss or body weight gain of ≥ 5 kg within the two months preceding study enrolment).
• •Chronic diarrhoea or steatorrhea or acute gastrointestinal infection within ≤ 3 months before study entry.
• •History of serious chronic disease including malignancy, chronic kidney disease (eGFR \< 60 ml/min), heart failure (NYHA ≥ III).
• •Any further condition, based on clinical judgment that may disqualify the candidate as an appropriate donor.
• •History of recent body weight change (defined as body weight loss or body weight gain of ≥ 5 kg within the two months preceding study enrolment).
• •HbA1C \> 6.5% or treatment with insulin or oral anti-diabetic medication.
• •Use of any weight loss medication or participation in a weight loss program
• •Use of immunosuppressive medication or immune modulators (glucocorticoids, methotrexate, tacrolimus, cyclosporine, thalidomide, interleukin-10 or -11) within the last three months preceding study enrolment.
• •Congenital or acquired immunodeficiencies.
• •Chronic or acute infectious diseases (specified under 6.2.1)
• •Drug abuse
• •Anatomical reconstruction of the nutrient passage (i.e. hemicolectomy, resection of small bowel, fundoplication etc) or cholecystectomy.
• •Chronic diarrhoea or acute gastrointestinal infection within ≤ 3 months before study entry.
• •History of serious chronic disease including malignancy, chronic kidney disease (eGFR \< 60 ml/min), heart failure (NYHA ≥ III).
• •Any further condition, based on clinical judgment that may disqualify the candidate as an appropriate donor.